Browse
Submit Data
Databases
API
Help

Dataset Information

20 Views

159 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 1006

Hospital Clinic Barcelona

ABSTRACT: Organisation EGAO00000000023

PROVIDER: EGAO00000000023 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Publications

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Puente Xose S XS Pinyol Magda M Quesada Víctor V Conde Laura L Ordóñez Gonzalo R GR Villamor Neus N Escaramis Georgia G Jares Pedro P Beà Sílvia S González-Díaz Marcos M Bassaganyas Laia L Baumann Tycho T Juan Manel M López-Guerra Mónica M Colomer Dolors D Tubío José M C JM López Cristina C Navarro Alba A Tornador Cristian C Aymerich Marta M Rozman María M Hernández Jesús M JM Puente Diana A DA Freije José M P JM Velasco Gloria G Gutiérrez-Fernández Ana A Costa Dolors D Carrió Anna A Guijarro Sara S Enjuanes Anna A Hernández Lluís L Yagüe Jordi J Nicolás Pilar P Romeo-Casabona Carlos M CM Himmelbauer Heinz H Castillo Ester E Dohm Juliane C JC de Sanjosé Silvia S Piris Miguel A MA de Alava Enrique E San Miguel Jesús J Royo Romina R Gelpí Josep L JL Torrents David D Orozco Modesto M Pisano David G DG Valencia Alfonso A Guigó Roderic R Bayés Mónica M Heath Simon S Gut Marta M Klatt Peter P Marshall John J Raine Keiran K Stebbings Lucy A LA Futreal P Andrew PA Stratton Michael R MR Campbell Peter J PJ Gut Ivo I López-Guillermo Armando A Estivill Xavier X Montserrat Emili E López-Otín Carlos C Campo Elías E

Nature 20110605 7354

Chronic lymphocytic leukaemia (CLL), the most frequent leukaemia in adults in Western countries, is a heterogeneous disease with variable clinical presentation and evolution. Two major molecular subtypes can be distinguished, characterized respectively by a high or low number of somatic hypermutations in the variable region of immunoglobulin genes. The molecular changes leading to the pathogenesis of the disease are still poorly understood. Here we performed whole-genome sequencing of four cases ...[more]

PMID: 21642962

Publication: 1/3

Similar Datasets

Hospital Clinic, IDIBAPS, CIBERER

Project description:Organisation EGAO00000000437

| EGAO00000000437 | EGA

Hospital Sant Joan de Deu, Barcelona

Project description:Organisation EGAO00000000258

| EGAO00000000258 | EGA

Hospital St Joan de DÃ©u, Barcelona

Project description:Organisation EGAO00000000251

| EGAO00000000251 | EGA

Mayo Clinic

Project description:Organisation EGAO00000000262

| EGAO00000000262 | EGA

Neuromuscular Unit. Neuropaediatrics Department. Hospital Sant Joan de DÃ©u Barcelona

Project description:Organisation EGAO00000000388

| EGAO00000000388 | EGA

Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.

Project description:AimTo investigate the efficacy and safety of adjuvant sorafenib after curative resection for patients with Barcelona Clinic Liver Cancer (BCLC)-stage C hepatocellular carcinoma (HCC).MethodsThirty-four HCC patients, classified as BCLC-stage C, received adjuvant sorafenib for high-risk of tumor recurrence after curative hepatectomy at a tertiary care university hospital. The study group was compared with a case-matched control group of 68 patients who received curative hepatectomy for HCC during the study period in a 1:2 ratio.ResultsThe tumor recurrence rate was markedly lower in the sorafenib group (15/34, 44.1%) than in the control group (51/68, 75%, P = 0.002). The median disease-free survival was 12 mo in the study group and 10 mo in the control group. Tumor number more than 3, macrovascular invasion, hilar lymph nodes metastasis, and treatment with sorafenib were significant factors of disease-free survival by univariate analysis. Tumor number more than 3 and treatment with sorafenib were significant risk factors of disease-free survival by multivariate analysis in the Cox proportional hazards model. The disease-free survival and cumulative overall survival in the study group were significantly better than in the control group (P = 0.034 and 0.016, respectively).ConclusionOur study verifies the potential benefit and safety of adjuvant sorafenib for both decreasing HCC recurrence and extending disease-free and overall survival rates for patients with BCLC-stage C HCC after curative resection.

| S-EPMC4910659 | biostudies-literature

Biochemical, Genetics & Rett Unit, Laboratory Department, Hospital Sant Joan de DÃ©u Barcelona,

Project description:Organisation EGAO00000000387

| EGAO00000000387 | EGA

A New Treatment-integrated Prognostic Nomogram of the Barcelona Clinic Liver Cancer System for Hepatocellular Carcinoma.

Project description:The nomogram of the Barcelona Clinic Liver Cancer (BCLC) has accurate outcome prediction. This study aims to propose a treatment-integrated nomogram derived from BCLC for patients with hepatocellular carcinoma (HCC). A total of 3,371 patients were randomly grouped into derivation (n = 2,247) and validation (n = 1,124) sets. Multivariate Cox proportional hazards model was used to generate the nomogram from tumor burden, cirrhosis, performance status (PS) and primary anti-cancer treatments. Concordance indices and calibration plots were used to evaluate the performance of nomogram. The derivation and validation sets had the same concordance index of 0.774 (95% confidence intervals: 0.717-0.826 and 0.656-0.874, respectively). In calibration plots, survival distributions predicted by the nomogram and observed by the Kaplan-Meier method were similar at 3- and 5-year for patients from derivation and validation sets. Validation group patients divided into 10 subgroups by the original and new treatment-integrated BCLC nomogram were used to evaluate the prognostic performance of integrating primary anti-cancer treatments. Compared to the nomogram of original BCLC system, the treatment-integrated nomogram of BCLC system had larger linear trend and likelihood ratio X2. In conclusion, based on the results of concordance index tests, integrating primary anti-cancer treatments into the BCLC system provides similar discriminatory ability.

| S-EPMC5554253 | biostudies-other

Identification of biomarkers for Barcelona Clinic Liver Cancer staging and overall survival of patients with hepatocellular carcinoma.

Project description:The aim of the current study was to identify biomarkers that correlate with the Barcelona Clinic Liver Cancer (BCLC) staging system and prognosis of patients with hepatocellular carcinoma (HCC). We downloaded 4 gene expression datasets from the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo), and screened for genes that were differentially expressed between HCC and normal liver tissues, using significance analysis of the microarray algorithm. We used a weighted gene co-expression network analysis (WGCNA) to identify hub genes that correlate with BCLC staging, functional enrichment analysis to associate hub genes with their functions, protein-protein interaction network analysis to identify interactions among hub genes, UALCAN analysis to assess gene expression levels based on tumour stage, and survival analyses to clarify the effects of hub genes on patients' overall survival (OS). We identified 50 relevant hub genes using WGCNA; among them, 13 genes (including TIGD5, C8ORF33, NUDCD1, INSB8, and STIP1) correlated with OS and BCLC staging. Significantly enriched gene ontology biological process terms included RNA processing, non-coding RNA processing and phosphodiester bond hydrolysis, and 6 genes were found to interact with 10 or more hub genes. We identified several candidate biomarkers that correlate with BCLC staging and OS of HCC. These genes might be used for prognostic assessment and selection of HCC patients for surgery, especially those with intermediate or advanced disease.

| S-EPMC6107203 | biostudies-literature

New idea for treatment strategies for Barcelona Clinic Liver Cancer stages based on a network meta-analysis.

Project description:Currently, the Barcelona Clinic Liver Cancer staging (BCLC) system still remains controversies in the management of hepatocellular carcinoma. We are trying to determine the best therapeutic strategy for each BCLC stage through a network meta-analysis and provide a new treatment idea.We conducted a systematic literature search of the PubMed, EMBASE, and Cochrane Library databases and extracted data from randomized controlled trials (RCTs) that compared various strategies. Network meta-analyses were conducted in ADDIS by evaluating different overall survival of each stage. Cumulative probability was used to rank the included strategies. A node-splitting model assessed whether direct and indirect evidence on a specific node was in agreement.Of the 24 included RCTs, 3667 patients were included. Based on the probability P values, the results showed that TACE plus surgical resection (SR) was the first choice for BCLC Stage A (P?=?.38 and P?=?.52 for 3- and 5-year OS, respectively). The application of SR was the best strategy for BCLC Stage B (P?=?.51 and P?=?.95 for 1- and 3-year OS, respectively). For Stage C, whole net connections could not be established in this research, but combined therapy seemed to produce better results based on 3 separated net connections (P?=?.92, P?=?.80, and P?=?.69 for 1-year OS).The updated therapy strategies discussed in this study are recommended. More importantly, we deemed that the recommended strategy for each patient may be subject to adjustment due to individual clinical factors. The applicable scope of each strategy should also be evaluated before application.

| S-EPMC5440153 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data